Table 2.
Adverse events and laboratory toxicities in all cohorts
| Adverse event | Vandetanib dose (mg)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| 100 mg (n = 8) | 200 mg (n = 9) | 300 mg (n = 6) | All (n = 23) | |||||
| CTCAE event | All | Grade 3/4 | All | Grade 3/4 | All | Grade 3/4 | All | Grade 3/4 |
| AST/ALT elevation | 4 | 1 | 7 | 0 | 5 | 3 | 16 | 4 |
| Diarrhea | 5 | 1 | 5 | 0 | 5 | 1 | 15 | 2 |
| Nausea/vomiting | 5 | 1 | 6 | 0 | 4 | 0 | 15 | 1 |
| Hyperglycemia | 7 | 0 | 6 | 0 | 4 | 0 | 15 | 0 |
| Fatigue | 5 | 1 | 6 | 0 | 2 | 1 | 13 | 2 |
| QTc prolongation | 4 | 0 | 5 | 0 | 4 | 1 | 13 | 1 |
| Anemia | 4 | 0 | 5 | 0 | 2 | 0 | 11 | 0 |
| Hypertension | 3 | 0 | 4 | 0 | 3 | 1 | 10 | 1 |
| Rash | 2 | 1 | 3 | 1 | 4 | 1 | 9 | 3 |
| Proteinuria | 1 | 0 | 4 | 0 | 4 | 0 | 9 | 0 |
| Mucositis | 3 | 0 | 2 | 0 | 1 | 1 | 6 | 1 |
| Neutropenia | 3 | 1 | 1 | 0 | 2 | 0 | 6 | 1 |